LANNETT COMPANY,INC. (NYSE:LCI) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 setting forth the votes of security holders at the
Annual Meeting of Stockholders of the Company held on January18,
2017. The Company has been informed by some of its stockholders
that the broker for such stockholders had been instructed to vote
the shares held by such shareholders in favor of the election of
all six director nominees, but incorrectly completed the proxy
card and voted to withhold votes from certain of the director
nominees. This amendment sets forth the votes as they should have
been received had the incorrectly completed proxy cards been
properly filled out. This voting error had no impact on the
outcome of the election, as each of the director nominees had
received the majority of all votes cast for the election as
directors of the Company.

Item 5.07 Submission of Matters to a Vote of Securities
Holders

The adjusted voting totals are as follows:

1. The stockholders elected all six director nominees to serve as
members of the Companys board of directors until the Companys
next Annual Meeting of Stockholders and until their respective
successors have been duly elected and qualified.

The number of votes cast for or withheld, for each nominee, was
as follows:

2. The stockholders ratified the appointment of Grant Thornton,
LLP as independent auditors. The number of votes cast for,
against, or abstained was as follows:

Votes For: 32,843,608

Votes Against: 110,216

Abstain: 70,002

About LANNETT COMPANY, INC. (NYSE:LCI)

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

LANNETT COMPANY, INC. (NYSE:LCI) Recent Trading Information

LANNETT COMPANY, INC. (NYSE:LCI) closed its last trading session up +0.65 at 19.45 with 843,185 shares trading hands.